Pacific Northwest SPORE Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2005
NCT00167648
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2005

Timeline

NOW
  • Now

Alternative names

Pacific Northwest SPORE (Specialized Projects in Oncology Research Excellence)

Active Ingredients

Drugs in Phase 2 Trials (3)

estradiol (progynon depot) (1 trial)

goserelin (zoladex) (1 trial)

leuprolide (lupron) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 3